Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Search


How Secure Is Your Firm's AI System?
November 01, 2024
What Law Firms Need to Know Before Trusting AI Systems with Confidential Information As artificial intelligence continues to revolutionize industries, the legal profession is no exception. Every authority agrees about the transformative impact AI is having on legal services. As law firms and corporate legal departments adopt AI technologies to streamline their practices, they must face the inevitable question: How secure are these AI systems?
Players On the Move
November 01, 2024
A look at moves among attorneys, law firms, companies and other players in entertainment law.
California Supreme Court to Consider Reach of Two Data Privacy Laws
November 01, 2024
California's Supreme Court will consider the reach of two data privacy laws cited in a recent appellate case that found an education vendor potentially liable for a breach of student information.
Are We Seeing the End of the Single-Tier Partnership Structure?
November 01, 2024
With a growing number of firms moving to a two-tier partnership structure, the question becomes what comes next for the dwindling number of major firms that don't have a nonequity tier. At what point do tradition and culture yield to change and progression?
Report: Window of Opportunity Opens for CRE Investment
November 01, 2024
After the last few years, a challenge for commercial real estate is knowing when to start investing again. Have markets hit bottom? Still, sinking down? The Federal Reserve cut rates by 50 basis points in September. Will they come down further? There's no guaranteed timing for investment success, but a recent Oxford Economics report suggests a window of opportunity that will be a good time to buy.
IP News
November 01, 2024
Federal Circuit: Falsely Claiming That a Product Feature is Patented Can Give Rise to a False Advertising Claim Under the Lanham Act Federal Circuit: A Prior Decision in an IPR Does Not Collaterally Estop the Patentee in a Subsequent Litigation Where Invalidity Must be Proven by 'Clear and Convincing Evidence'
Unchargeable Conduct
November 01, 2024
Until the U.S. Sentencing Commission closes the unchargeable conduct loophole — or until the U.S. Supreme Court intervenes — criminal defense practitioners would be wise to take prophylactic action to protect their clients during plea negotiations. Setting forth the permissible bounds of "relevant conduct" in plea agreements can help avoid 11th-hour surprises for the defense.
Landlord & Tenant Law
November 01, 2024
Charges for Keys Constituted Reduction In Service
Upcoming Event
November 01, 2024
34th Annual Entertainment Law Institute Austin, TX, Nov. 21-22
Developing Client Personas Can Help Maximize Marketing and Business Development
November 01, 2024
Who are your ideal clients and why do they (or should they) hire you? This simple but key question for marketing and business development is often deceptively challenging to answer. Building and implementing comprehensive client personas enables lawyers, practices and firms to refine their marketing and business development strategies to attract clients that align with their expertise, experience and values.

MOST POPULAR STORIES

  • Surveys in Patent Infringement Litigation: The Next Frontier
    Most experienced intellectual property attorneys understand the significant role surveys play in trademark infringement and other Lanham Act cases, but relatively few are likely to have considered the use of such research in patent infringement matters. That could soon change in light of the recent admission of a survey into evidence in <i>Applera Corporation, et al. v. MJ Research, Inc., et al.</i>, No. 3:98cv1201 (D. Conn. Aug. 26, 2005). The survey evidence, which showed that 96% of the defendant's customers used its products to perform a patented process, was admitted as evidence in support of a claim of inducement to infringe. The court admitted the survey into evidence over various objections by the defendant, who had argued that the inducement claim could not be proven without the survey.
    Read More ›
  • In the Spotlight
    On May 9, 2003, the U.S. Attorney's Office for the District of Massachusetts announced that Bayer Corporation, the pharmaceutical manufacturer, had been sentenced and ordered to pay a criminal fine of $5,590,800 stemming from its earlier plea of guilty to violating the Federal Prescription Drug Marketing Act by failing to list with the FDA its drug product, Cipro, that was privately labeled for an HMO. Such listing is required under the federal Food, Drug &amp; Cosmetic Act. The Federal Prescription Drug Marketing Act, Pub. L. 100-293, enacted on April 22, 1988, as modified on August 26, 1992 by the Prescription Drug Amendments (PDA) Pub. L. 102-353, 106 Stat. 941, amended sections 301, 303, 503, and 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. '' 331, 333, 353, 381, to establish requirements for distributing prescription drug samples.
    Read More ›